Adriatic sea
Trieste
[email protected]://www.icgeb.org
Mauro Giacca, MD PhDDirector, ICGEB Trieste, Italy
Biotecnologie per lo sviluppo internazionale
IL SISTEMA SCIENTIFICO FVG E LA COLLABORAZIONE TRA RICERCA, IMPRESA E GOVERNANCE PUBBLICA NELL’AMBITO DELLE BIOTECNOLOGIE
XIII Conferenza annuale del Coordinamento regionale degli Enti di Ricerca
AREA Science Park Padriciano 99 - Trieste Centro Congressi (Edificio C - Conference Hall )16 DICEMBRE 2014 - ORE 9.30
Le biotecnologie e le loro svariate applicazioni nei Centri di
ricerca del territorio, dall’ambito alimentare all’ingegneria
genetica, saranno il tema centrale della Conferenza annuale
degli Enti di Ricerca del Friuli Venezia Giulia.
Un incontro per presentare anche i recenti nuovi percorsi
di formazione sviluppati in condivisione con le aziende
leader nel settore, e per affrontare le nuove sfi de di Ricerca,
Innovazione e Trasferimento tecnologico.
Da sempre la crescita competitiva della regione è tra gli
obiettivi principali della Conferenza annuale degli Enti di
Ricerca del Friuli Venezia Giulia. Un traguardo raggiungibile
illustrando le esperienze già maturate, approfondendo le
possibili applicazioni, integrando i programmi di ricerca
e incrementando ulteriormente l’interazione tra i Centri di
ricerca nazionali e internazionali e le imprese.
Ministero dell ’ Istruzione,dell ’Università e della Ricerca
COME RAGGIUNGERE LA SEDEDELLA CONFERENZA
da Trieste cittàvia Fabio Severo - via A. Valerio -al bivio H girare a sinistrae ancora a sinistra e proseguire finoall’uscita Padriciano(indicazioni AREA in loco)
dall’autostrada A4uscita casello Lisert - proseguire fino all’uscita Padriciano (indicazioni AREA in loco)
martedì 16 dicembre, ore 9.30AREA Science Park Trieste, Padriciano 99Centro Congressi(Edificio C – Conference Hall)
SEGRETERIA ORGANIZZATIVA
Studio Sandrinelli srlRelazioni pubbliche e comunicazionevia Carducci 2234125 Triestetel. +39 040 [email protected]
PROGRAMMA PROMEMORIA
Per ulteriori informazioni, il sito web di riferimento è: www.area.trieste.it/conferenzaCER_2014
SEGRETERIA SCIENTIFICA
Ginevra ToniniUfficio Coordinamento e Internazionalizzazionedegli Enti di Ricerca regionali
Servizio Formazione Progettazione e Gestione progetti
AREA Science Park34149 Padriciano, Triestetel. +39 040 [email protected]
Ministero degli Affari Esterie della Cooperazione Internazionale
9.30 RegistrazioneChair: Alfonso FranciosiPresidente Elettra-Sincrotrone Trieste S.C.p.A.
9.45 WelcomeAdriano De MaioPresidente AREA Science Park
10.00 Loredana PanaritiAssessore al lavoro, formazione, istruzione, pari opportunità, politiche giovanili e ricerca, Regione Autonoma Friuli Venezia Giulia
Il Network del Sistema Scientifico regionale: finalità, ruoli e nuove prospettive di collaborazione tra gli attori regionali della ricerca in Friuli Venezia Giulia
10.15 Diego BravarConfi ndustria Trieste
La collaborazione pubblico-privata per nuovi percorsi formativi: l’ITS Nuove Tecnologie della Vita
10.30 Alberto Felice De ToniRettore dell’Università degli Studi di Udine
Le biotecnologie per la qualità e la sicurezza nel campo alimentare
10.45 Maurizio FermegliaRettore dell’Università degli Studi di Trieste
Nano-bio-med: un’area strategica di sviluppo scientifico e tecnologico
11.00 Mauro GiaccaDirettore Generale ICGEB - International Centre for Genetic Engineering and Biotechnology
Biotecnologie per lo sviluppo internazionale
11.15 Guido MartinelliDirettore SISSA - Scuola Internazionale Superiore di Studi Avanzati
Ricerca in biologia molecolare, biotecnologie e l’impatto sul territorio e sull’impresa
11.30 Ugo FerreroDirezione Generale per la Promozione del Sistema Paese, Ministero degli Affari Esteri e della Cooperazione Internazionale
Il sistema scientifico e la promozione del Sistema Paese
11.45 Conclusioni a cura di Federico CinquepalmiDirezione Generale per l’Internazionalizzazione della Ricerca,Ministero dell’Istruzione, dell’Università e della Ricerca
Ebola Outbreak
The 2014 Ebola epidemic
Likely host = bats
1 in 2
How do you get the Ebola virus?
1 Body fluids of a person who is sick with or has died from Ebola.
2 Objects contaminated with the virus
3 Infected fruit bats or primates
Early Symptoms
FeverHeadacheFatigueDiarrheaVomiting
Stomach painUnexplained bleeding or bruisingMuscle pain
When is someone able to spreadthe disease to others?Ebola only spreadswhen people are sick.
After 21 days,MONTHS SFM T TW
541 326 12117 8 10913 191814 15 171620 262521 22 242327 28 29 3130
Virus di Ebola
Vaccini ricombinanti contro il virus di Ebola
Anticorpi monoclonali contro il virus di Ebola
Biopharmaceutical Products
InsulinHuman Growth Hormone (hGH)α-InterferonHepatitis B VaccineTissue Plasminogen Activator (TPA)Erythropoietin-αγ-InterferonGranulocyte Colony Stimulating Factor (G-CSF)Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)Interleukin 2Factor VIIIβ-InterferonDNase (Pulmozyme®)Glucocerebrosidase (Cerezyme®)ReoPro®
Source: Consulting Resources Corp.
Product
198219851986198619871989199019911991199219921993199319941994
Year
Humira (adalimumab) – Monoclonal antibody against TNFalpha
Enbrel (etanercept) – Fusion between the p75 TNFalpha receptor and an Ig
Remicade (infliximab) – Monoclonal antibody against TNFalpha
Seretide/Advair – Salmeterol and fluticasone
Lantus – insulin glargine
Rituxan (rituximab) – monoclonal antibody against B cell CD20
Avastin - monoclonal antibody against VEGF-A
Herceptin (trastuzumab) – monoclonal antibody against HER2/neu
Crestor (rosuvastatina) - statin
Abilifty (aripiprazolo) – schizophrenia and bipolar disorders
Late ‘70s and early ‘80s: Very successful biotech companies are born in the US (Genentech, 1976; Biogen, 1978; Amgen, 1980; Immunex, 1981; Chiron, 1981; Genzyme 1981)
early ‘80s: UNIDO functionaries in Vienna conceive the idea of a biotech Centre for developing countries
The early days in ICGEB history
1982: First meeting organized by UNIDO in Belgrade, Serbia
Late ‘70s and early ‘80s: Very successful biotech companies are born in the US (Genentech, 1976; Biogen, 1978; Amgen, 1980; Immunex, 1981; Chiron, 1981; Genzyme 1981)
early ‘80s: UNIDO functionaries in Vienna conceive the idea of a biotech Centre for developing countries
1982: First meeting organized by UNIDO in Belgrade, Serbia
1983: Foundation meeting in Madrid, Spain; Italy puts forward its candidature to host the Centre
1987: ICGEB is founded with two seats, one in Trieste, Italy and one in New Delhi, India
The early days in ICGEB history
To provide a Centre of excellence for research and
training in genetic engineering and
biotechnology addressed to developing countries and economies in transition
Developing knowledge
80+ Signatory States, 60+ Member States, 3 Components:Trieste (Italy) - New Delhi (India) - CapeTown (South Africa)
and a network of 40+ Affiliated Centres
Developing knowledge
CapeTown, South Africa
New Delhi, India
Trieste, Italy
ICGEB An intergovernmental organization in the United Nations Common System
• Cutting-edge scientific research in its laboratories in Trieste, New Delhi and Cape Town
• Advanced education supported by long- and short-term fellowships for PhD students and post-docs
• Organisation of Meetings, Courses and Workshops
• Competitive research grants for scientists in its Member Countries
• Technology transfer to industry for the production of biotherapeutics and diagnostics
The 5 instruments of action
ICGEB contents on iTunes USeminars and meeting presentations recorded in HD movie format and grouped in 28 different Collections
http://itunes.apple.com/us/institution/international-centre-for-genetic/id425107665
10/09/2011 - 03/05/2014
Tot. actions 347377
Browse Subscribe Download Stream Enclosure
170251 41931 81606 37551 16038
What's next?
80
How long shall we live?
60
40
20
Ancient Rome
22
Life
exp
ecta
ncy
(yea
rs)
1900
49
1970
70
2000
76
~1900 70 30
21
27
7
Life expectancy at birth in developed countries
Aging correlates with the sudden or progressive exhaustion of regenerative capacity in most organs and tissues after birth
Rubens, Philadelphia
Nicolas-Sebastien Adam, Paris, Louvre
"The hound of Zeus, the tawny eagle, ..... feasting on thy liver til he hath gnawn it black"
Aeschylys, Prometeus Bound
There is a pressing need to develop novel therapeutics for highly prevalent degenerative disorders
Ischemic cardiomyopathy and heart failure (HF)15 million HF patients worldwide; 50% of patients with HF die within 4 yearsNeurodegeneration30% of people over 80 years develop Alzheimer disease, and 1-3% of those over 65 years of age develop Parkinson's diseaseDiabetes mellitus>170 million people affected worldwide. Both Type 1 (autoimmune) and Type 2 (due to insulin resistance) diabetes are eventually determined by β-cell lossRetinal degenerationAge-related macular degeneration (AMD) is the leading cause of irreversible blindness, mostly affecting people over the age of 50. Prevalence of 30% in people over age 75 Presbycusis (Age-related hearing loss)Due to degeneration of hair cells of the cochlea and giant stereociliary cells. Affects >50% people over age 75
Biotherapeutics for degenerative conditions
Synthetic peptides or recombinant proteins
Gene TherapyProtein-coding cDNA, siRNA, miRNA, miRNA inhibitor. Which vector? Syringe containing factor,
vector or stem cells
Cell TherapyStem cell? Source?
Tissue protection Improved function
Regeneration
Cardiovascular disorders are the most common, serious, chronic, life-threatening disease causing more deaths, disability and economic costs than all other diseases, including cancer.
More than 1 person out of 3 dies because of cardiovascular disorders, including myocardial infarction (42%) or stroke (36%). The total deaths due to these diseases per year is >17 million people worldwide.
More than 50% of patients with ischemic cardiomyopathy develop towards heart failure; t
Causes of deathWorld Health Organization, 2011
Global Atlas on cardiovascular disease prevention and control, WHO 2011
The tremendous burden of cardiovascular disorders